NASDAQ:ATRC AtriCure (ATRC) Stock Price, News & Analysis $58.97 -0.33 (-0.56%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$58.64 -0.34 (-0.57%) As of 10/23/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About AtriCure Stock (NASDAQ:ATRC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AtriCure alerts:Sign Up Key Stats Today's Range$58.53▼$59.5650-Day Range$44.77▼$60.7752-Week Range$25.36▼$61.70Volume497,103 shsAverage Volume900,345 shsMarket Capitalization$3.00 billionP/E Ratio280.82Dividend YieldN/APrice Target$55.70Consensus RatingHold Company Overview AtriCure, Inc. is a medical device company that develops and sells products for the surgical treatment of atrial fibrillation (AFib) and related conditions. Its technologies are designed to support cardiac surgeons and electrophysiologists performing tissue ablation, left atrial appendage management and other procedures intended to restore or maintain normal heart rhythm. The company’s product portfolio includes the AtriClip device, which is used to exclude the left atrial appendage, along with surgical ablation systems such as the Isolator Synergy clamps and cryoablation products. AtriCure also offers the EPi-Sense system for hybrid and minimally invasive AFib procedures, as well as products used in cardiac and thoracic pain-management procedures. Founded in 2000 and headquartered in Mason, Ohio, AtriCure serves hospitals and medical professionals in the United States and international markets. Its products are marketed for use in open, minimally invasive and hybrid surgical approaches, with the company focused on expanding treatment options for patients with AFib and other heart-rhythm disorders.AI Generated. May Contain Errors. Read More AtriCure Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreATRC MarketRank™: 2.414163090125 of 5 starsAtriCure scored higher than 48% of companies evaluated by MarketBeat, and ranked 524th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.2 / 5Analyst RatingHold Consensus RatingAtriCure has received a consensus rating of Hold. The company's average rating score is 2.42, and is based on no strong buy ratings, 6 buy ratings, 5 hold ratings, and 1 sell rating.Downside RiskAtriCure has a consensus price target of $55.70, representing about 5.5% downside from its current price of $58.97.Amount of Analyst CoverageAtriCure has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about AtriCure's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth55.17% Earnings GrowthEarnings for AtriCure are expected to grow by 55.17% in the coming year, from $0.29 to $0.45 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AtriCure is 280.82, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.39.Price to Earnings Ratio vs. SectorThe P/E ratio of AtriCure is 280.82, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.33.Price to Book Value per Share RatioAtriCure has a P/B Ratio of 5.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about AtriCure's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.87% of the float of AtriCure has been sold short.Short Interest Ratio / Days to CoverAtriCure has a short interest ratio ("days to cover") of 2.61, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AtriCure has recently increased by 12.60%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAtriCure does not currently pay a dividend.Dividend GrowthAtriCure does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.85 News SentimentAtriCure has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for AtriCure this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for ATRC on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows3 people have added AtriCure to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, AtriCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,317,897.00 in company stock.Percentage Held by Insiders4.00% of the stock of AtriCure is held by insiders.Percentage Held by Institutions99.11% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AtriCure's insider trading history. Receive ATRC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATRC Stock News HeadlinesCitizens Jmp Forecasts Strong Price Appreciation for AtriCure (NASDAQ:ATRC) StockOctober 23 at 1:30 AM | americanbankingnews.comAtriCure (ATRC) Stock Gets Fair Value Bump As Analysts Weigh Procedure Growth And RisksOctober 4, 2026 | finance.yahoo.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.October 25 at 1:00 AM | Behind the Markets (Ad)Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Atricure (ATRC)October 4, 2026 | theglobeandmail.comConfira a cotação ATRC hoje e acompanhe as ações AtriCure em tempo real.September 27, 2026 | br.investing.comAtriCure (ATRC) Stock Looks Rich Against Its Sales BaseSeptember 25, 2026 | finance.yahoo.comWhy AtriCure (ATRC) Is Back In The SpotlightSeptember 25, 2026 | finance.yahoo.comInsider Selling: AtriCure (NASDAQ:ATRC) Insider Sells 4,519 Shares of StockSeptember 25, 2026 | insidertrades.comSee More Headlines ATRC Stock Analysis - Frequently Asked Questions How have ATRC shares performed this year? AtriCure's stock was trading at $39.56 at the beginning of the year. Since then, ATRC shares have increased by 49.1% and is now trading at $58.97. How were AtriCure's earnings last quarter? AtriCure, Inc. (NASDAQ:ATRC) issued its quarterly earnings results on Thursday, July, 23rd. The medical device company reported $0.18 earnings per share for the quarter, topping analysts' consensus estimates of $0.00 by $0.18. The medical device company earned $153.60 million during the quarter, compared to analysts' expectations of $151.80 million. AtriCure had a trailing twelve-month return on equity of 2.34% and a net margin of 1.85%. Read the conference call transcript. Does AtriCure have any subsidiaries? AtriCure subsidiaries include SentreHEART. Who are AtriCure's major shareholders? Top institutional investors of AtriCure include Yousif Capital Management LLC (0.03%), Diversify Advisory Services LLC (0.02%), State of Alaska Department of Revenue (0.02%) and First Bank & Trust (0.02%). Insiders that own company stock include Salvatore Privitera, Justin J Noznesky, Karl S Dahlquist, Vinayak Doraiswamy, Sven Wehrwein, Regina E Groves, Karen Prange and Maggie Yuen. View institutional ownership trends. How do I buy shares of AtriCure? Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AtriCure own? Based on aggregate information from My MarketBeat watchlists, some other companies that AtriCure investors own include Chevron (CVX), Neurocrine Biosciences (NBIX), NVIDIA (NVDA), Verizon Communications (VZ), C3.ai (AI), CVS Health (CVS) and Delta Air Lines (DAL). Company Calendar Last Earnings7/23/2026Today10/25/2026Next Earnings (Confirmed)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ATRC's financial health is in the Green zone, according to TradeSmith. ATRC has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:ATRC CIK1323885 Webwww.atricure.com Phone(513) 755-4100Fax513-755-4567Employees1,350Year Founded2000Price Target and Rating Average Price Target for AtriCure$55.70 High Price Target$68.00 Low Price Target$36.00 Potential Upside/Downside-5.5%Consensus RatingHold Rating Score (0-4)2.42 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)$0.21 Trailing P/E Ratio280.82 Forward P/E Ratio203.34 P/E GrowthN/ANet Income-$11.45 million Net Margins1.85% Pretax Margin2.12% Return on Equity2.34% Return on Assets1.77% Debt Debt-to-Equity Ratio0.14 Current Ratio4.22 Quick Ratio3.19 Sales & Book Value Annual Sales$569.62 million Price / Sales5.27 Cash Flow$0.31 per share Price / Cash Flow188.41 Book Value$9.89 per share Price / Book5.96Miscellaneous Outstanding Shares50,866,000Free Float48,831,000Market Cap$3.00 billion OptionableOptionable Beta1.24 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:ATRC) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AtriCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AtriCure With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.